Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C35H42N4O5 |
| Molecular Weight | 598.7318 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(CN5CCC(CC5)C(O)=O)C=C4
InChI
InChIKey=ZVPVPYWMFMUFEZ-UHFFFAOYSA-N
InChI=1S/C35H42N4O5/c1-37(33(40)28-13-11-26(12-14-28)25-39-19-15-29(16-20-39)34(41)42)23-24-38-21-17-30(18-22-38)44-35(43)36-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,29-30H,15-25H2,1H3,(H,36,43)(H,41,42)
| Molecular Formula | C35H42N4O5 |
| Molecular Weight | 598.7318 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 04:19:57 GMT 2025
by
admin
on
Wed Apr 02 04:19:57 GMT 2025
|
| Record UNII |
A6X64T4LZ4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
A6X64T4LZ4
Created by
admin on Wed Apr 02 04:19:57 GMT 2025 , Edited by admin on Wed Apr 02 04:19:57 GMT 2025
|
PRIMARY | |||
|
909800-36-8
Created by
admin on Wed Apr 02 04:19:57 GMT 2025 , Edited by admin on Wed Apr 02 04:19:57 GMT 2025
|
PRIMARY | |||
|
57459433
Created by
admin on Wed Apr 02 04:19:57 GMT 2025 , Edited by admin on Wed Apr 02 04:19:57 GMT 2025
|
PRIMARY | |||
|
DTXSID401027776
Created by
admin on Wed Apr 02 04:19:57 GMT 2025 , Edited by admin on Wed Apr 02 04:19:57 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
Coordination with OATP1B3 inhibitors (e.g. rifampicin, cyclosporine, etc.) could lead to an increase in systemic exposure of the active metabolite.
|
||
|
TARGET -> INHIBITOR |
THRX-195518 possesses activity at target muscarinic receptors that was slightly lower (approximately one-third to one-tenth) than revefenacin.
BINDING
Ki
|
||
|
TARGET -> INHIBITOR |
THRX-195518 possesses activity at target muscarinic receptors that was slightly lower (approximately one-third to one-tenth) than revefenacin.
BINDING
Ki
|
||
|
TRANSPORTER -> SUBSTRATE |
Coordination with OATP1B1 inhibitors (e.g. rifampicin, cyclosporine, etc.) could lead to an increase in systemic exposure of the active metabolite.
|
||
|
TARGET -> INHIBITOR |
THRX-195518 possesses activity at target muscarinic receptors that was slightly lower (approximately one-third to one-tenth) than revefenacin.
BINDING
Ki
|
||
|
TARGET -> INHIBITOR |
THRX-195518 possesses activity at target muscarinic receptors that was slightly lower (approximately one-third to one-tenth) than revefenacin.
BINDING
Ki
|
||
|
BINDER->LIGAND |
|
||
|
TARGET -> INHIBITOR |
THRX-195518 possesses activity at target muscarinic receptors that was slightly lower (approximately one-third to one-tenth) than revefenacin.
BINDING
Ki
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
MAJOR
|
